vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and Hyperliquid Strategies Inc (PURR). Click either name above to swap in a different company.
InMed Pharmaceuticals Inc. is the larger business by last-quarter revenue ($820.2K vs $500.0K, roughly 1.6× Hyperliquid Strategies Inc). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -60892.6%, a 60645.3% gap on every dollar of revenue.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
INM vs PURR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $500.0K |
| Net Profit | $-2.0M | $-304.5M |
| Gross Margin | 22.5% | — |
| Operating Margin | -247.3% | -57509.2% |
| Net Margin | -247.3% | -60892.6% |
| Revenue YoY | -26.2% | — |
| Net Profit YoY | 21.2% | — |
| EPS (diluted) | $-0.51 | $-7.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $820.2K | $500.0K | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.2M | — |
| Q4 25 | $-2.0M | $-304.5M | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | 22.5% | — | ||
| Q3 25 | 36.0% | — | ||
| Q2 25 | 44.2% | — | ||
| Q1 25 | 13.9% | — | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 36.3% | — | ||
| Q1 24 | 24.7% | — |
| Q4 25 | -247.3% | -57509.2% | ||
| Q3 25 | -154.2% | — | ||
| Q2 25 | -137.1% | — | ||
| Q1 25 | -168.1% | — | ||
| Q4 24 | -231.6% | — | ||
| Q3 24 | -132.7% | — | ||
| Q2 24 | -150.5% | — | ||
| Q1 24 | -146.9% | — |
| Q4 25 | -247.3% | -60892.6% | ||
| Q3 25 | -154.2% | — | ||
| Q2 25 | -137.1% | — | ||
| Q1 25 | -168.1% | — | ||
| Q4 24 | -231.6% | — | ||
| Q3 24 | -132.7% | — | ||
| Q2 24 | -151.0% | — | ||
| Q1 24 | -146.9% | — |
| Q4 25 | $-0.51 | $-7.43 | ||
| Q3 25 | $-0.44 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | $-1.94 | — | ||
| Q4 24 | $-3.64 | — | ||
| Q3 24 | $-2.71 | — | ||
| Q2 24 | $2.39 | — | ||
| Q1 24 | $-3.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $281.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $589.8M |
| Total Assets | $11.2M | $616.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $281.9M | ||
| Q3 25 | $9.4M | — | ||
| Q2 25 | $11.1M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $5.6M | — | ||
| Q2 24 | $6.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | $9.6M | $589.8M | ||
| Q3 25 | $11.6M | — | ||
| Q2 25 | $13.4M | — | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $9.2M | — | ||
| Q1 24 | $11.1M | — |
| Q4 25 | $11.2M | $616.6M | ||
| Q3 25 | $13.4M | — | ||
| Q2 25 | $15.6M | — | ||
| Q1 25 | $9.3M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -165.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
